Use of very low-dose naltrexone during opiate detoxification

被引:16
作者
Mannelli, P
Gottheil, E
Buonanno, A
De Risio, S
机构
[1] Thomas Jefferson Univ, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA
[2] Univ Cattolica Sacro Cuore, Ist Psichiat & Psicol, Unita Psichiatria Clin & Farmacodipendenze, Rome, Italy
关键词
opiate antagonists; detoxification; withdrawal; receptor occupancy;
D O I
10.1300/J069v22n02_05
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The use of antagonist drugs to reduce the duration of opiate detoxification severely enhances withdrawal symptoms. To investigate the feasibility of administering antagonists with opiates without intense withdrawal during detoxification, 5 methadone maintained patients were evaluated while tapering methadone and receiving at the same time very low (0.125 mg), then increasing daily doses of naltrexone in the course of a 6-day, day hospital treatment. Reduced quantities of adjunctive medications were administered, as compared to the standard protocols, the treatment was completed without incidents or particular discomfort and all patients were easily induced to naltrexone maintenance by the day of discharge. Controlled studies will clarify whether very low-dose naltrexone provides a safe and comfortable detoxification technique to reduce withdrawal intensity and duration without the problems of heavy sedation, as suggested by the description of these clinical cases.
引用
收藏
页码:63 / 70
页数:8
相关论文
共 15 条
[1]   Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability [J].
Crain, SM ;
Shen, KF .
PAIN, 2000, 84 (2-3) :121-131
[2]   ULTRA-LOW CONCENTRATIONS OF NALOXONE SELECTIVELY ANTAGONIZE EXCITATORY EFFECTS OF MORPHINE ON SENSORY NEURONS, THEREBY INCREASING ITS ANTINOCICEPTIVE POTENCY AND ATTENUATING TOLERANCE DEPENDENCE DURING CHRONIC COTREATMENT [J].
CRAIN, SM ;
SHEN, KF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10540-10544
[3]  
Goldstein A, 1973, Adv Biochem Psychopharmacol, V8, P471
[4]   NALTREXONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN THE MANAGEMENT OF OPIOID DEPENDENCE [J].
GONZALEZ, JP ;
BROGDEN, RN .
DRUGS, 1988, 35 (03) :192-213
[5]   PARADOXICAL ANALGESIA INDUCED BY NALOXONE AND NALTREXONE [J].
GREELEY, JD ;
LE, AD ;
POULOS, CX ;
CAPPELL, H .
PSYCHOPHARMACOLOGY, 1988, 96 (01) :36-39
[6]  
HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515
[7]  
Jaffe JH., 1997, Substance abuse, V3rd, P158
[8]   POTENTIATION OF PENTAZOCINE ANALGESIA BY LOW-DOSE NALOXONE [J].
LEVINE, JD ;
GORDON, NC ;
TAIWO, YO ;
CODERRE, TJ .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (05) :1574-1577
[9]   Serendipitous rapid detoxification from opiates: the importance of time-dependent processes [J].
Mannelli, P ;
De Risio, S ;
Pozzi, G ;
Janiri, L ;
De Giacomo, M .
ADDICTION, 1999, 94 (04) :589-591
[10]   Diagnostic and Statistical Manual of Mental Disorders [J].
Mittal, Vijay A. ;
Walker, Elaine F. .
PSYCHIATRY RESEARCH, 2011, 189 (01) :158-159